摘要
1例86岁男性患者因疑似焦虑症,给予氟哌噻吨美利曲辛1片,1次/d口服。用药后逐渐出现精神萎靡、嗜睡、乏力、进食减少。第19天出现进食恶心。第28天进展为进食吞咽困难,无法站立行走,反应迟钝。血电解质检查:钾4.0 mmol/L,钠121mmol/L,氯84 mmol/L。诊断低钠、低氯血症。氟哌噻吨美利曲辛减至1/2片、1次/d。次日患者精神及进食状态明显好转。1周后氟哌噻吨美利曲辛减至1/4片、1次/d。2周后停用氟哌噻吨美利曲辛。患者恢复正常。复查血电解质:钾4.3 mmol/L,钠135 mmol/L,氯98 mmol/L。
An 86-year-old man received one flupentixol and melitraeen tablet once daily for suspected anxiety disorder. After starting treatment, he gradually developed listlessness, somnolence, weakness, and anorexia. On days 19, he developed nausea. On days 28, his symptoms progressed to dysphagia, inability to stand or walk, slow response. Serum electrolyte test showed the followed levels： potassium 4.0 mmol/L, sodium 121 mmol/L, chlorine 84 mmol/L. Hyponatremia and hypochloremia were diagnosed. Flupentixol and melitraeen tablets decreased to 1/2 tablet once daily. The next day, his mental status and appetite improved remarkably. One week later, flupentixol and melitracen tablets decreased to 1/4 tablet once daily. Two weeks later, flupentixol and melitracen tablets was discontinued. The patient returned to normal. A repeat serum electrolyte test showed a potassium level of 4.3 retool/L, a sodium level of 135 mmol/L, and a chlorine level of 98 mnlo//L.
出处
《药物不良反应杂志》
2012年第5期310-312,共3页
Adverse Drug Reactions Journal
